BridgeBio Pharma 3Q 2026: Revenue $353.17M, Net income ($83M), EPS ($0.42) — 10-Q Summary
BridgeBio Pharma reported 3Q 2026 revenue of $353.17M, up 192.6% YoY, with net loss narrowing to $83M. EPS improved to ($0.42). Growth driven by Attruby product revenue and Beyonttra royalties. FDA review decisions pending for three drugs.
How this was made
The 30-second read
Why it matters
The combination of sharply higher revenue, narrowing net loss, and newly accepted FDA priority-review applications with target decision months creates both fundamental and event-driven trading catalysts.
Market read
Traders can use the reported quarterly financial improvements and the stated FDA decision windows to adjust probability-weighted expectations and near-term risk management.
What to watch
The summary does not provide guidance, cash balance, or detailed segment profitability, so traders may overreact to revenue growth without assessing burn rate and runway beyond the stated 12 months.
Background
The piece is a brief summary of BridgeBio Pharma’s 3Q 2026 10-Q, highlighting financial results, product/royalty momentum, and FDA priority-review acceptance for BBP-418-related applications.
Ticker impact
BridgeBio Pharma reported 3Q 2026 revenue of $353.17M and narrowed net loss to $83M, plus FDA priority-review acceptance for BBP-418 programs.
Likely upward bias as traders price in improving profitability and upcoming FDA decision timelines.
The article provides concrete quarterly financial datapoints and new FDA priority-review acceptance with stated target decision months, both of which can drive sentiment and positioning.
Market effects
Biotech investors may re-rate commercial-stage rare-disease revenue durability and the probability-weighted value of near-term FDA decisions.
No direct regional macro or cross-border market mechanism beyond mention of approvals in Australia, Brazil, and royalties growth in Europe and Japan.
FDA priority-review timelines can influence broader sentiment toward similar late-stage biotech programs, but the article is company-specific.
Counterpoint
Revenue growth may be driven by product revenue and partner collections that could be volatile, and R&D and commercial spending increased, which may pressure future margins.
Key entities
- companyBridgeBio Pharma, Inc.
Reported 3Q 2026 revenue growth, narrowed net loss, and FDA priority-review acceptance for BBP-418 programs.
- programBBP-418 (encaleret and infigratinib)
FDA accepted applications for priority review with target decisions in November 2026, February 2027, and May 2027 (as stated).
- productsAttruby and Beyonttra
Attruby revenue rose year over year; Beyonttra royalties increased with expanded sales and approvals in Australia and Brazil (as stated).
